acts as a dopamine antagonist to D2 receptors in the mesolimbic pathway, and works similarly on serotonin 5HT2A receptors in the frontal cortex. At doses between 2.5 and 5 mg, olanzapine has been shown to be more effective than placebo at reducing stuttering symptoms, and may serve as a first-line pharmacological treatment for stuttering based on the preponderance of its efficacy data. However, other medications are generally better tolerated with less weight gain and less risk of metabolic effects than olanzapine. Risperidone and haloperidol have also shown effectiveness in the treatment of stuttering. However, haloperidol in particular often result in poor long-term compliance due to concerning side effects such as movement disorders and prolactin elevation, which can also occur with risperidone. Other dopamine active medications reported to positively treat stuttering include aripiprazole, asenapine, lurasidone, which tend to be better tolerated than olanzapine with less weight gain. All these medications as well as olanzapine can carry the potential risk of a long-term movement disorder known as tardive dyskinesia. The investigational compound, ecopipam, is unique from other dopamine antagonists in that it acts on D1 receptors instead of D2, owing little, if any risk, of movement disorders. An open label study of ecopipam in adults demonstrated significantly improved stuttering symptoms with no reports of parkinsonian-like movement disorders or tardive dyskinesia which can be seen with D2 antagonists. In addition, ecopipam had no reported weight gain, but instead has been reported to lead to weight loss. In a preliminary study, it was well tolerated in subjects, effectively reduced stuttering severity, and was even associated in a short-term study with improved quality of life in persons who stutter. Further research is still warranted, but this novel mechanism is showing promise in the pharmacologic treatment of stuttering. Support With existing behavioral and prosthetic treatments providing limited relief and pharmacologic treatments in need of FDA approval for widespread use, support groups and the self-help movement continue to gain popularity and support from professionals and from people who stutter. Self-help groups provide people who stutter a shared forum within which they can access resources and support from others facing the same challenges of stuttering. One of the basic tenets behind the self-help movement is that since a cure does not exist, quality of life can be improved by not thinking about the stammer for prolonged periods. Psychoanalysis has claimed success in the treatment of stuttering. Hypnotherapy has